ID: hyp-SDA-2026-04-09-gap-debate-20260409-2
Hypothesis
Co-chaperone Hijacking Strategy
Bifunctional PROTACs that simultaneously bind HSP70's substrate-binding domain and recruit CHIP ubiquitin ligase specifically to tau complexes, creating synthetic ternary complexes that channel tau toward proteasomal degradation while pr.
drug discovery
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
Bifunctional PROTACs that simultaneously bind HSP70's substrate-binding domain and recruit CHIP ubiquitin ligase specifically to tau complexes, creating synthetic ternary complexes that channel tau toward proteasomal degradation while preserving HSP70's normal folding functions.
🧬 Mechanism
🔗 Mechanism from KG for HSPA1A
Auto-built from this analysis's top knowledge-graph edges.
graph TD
HSPA1A["HSPA1A"] -->|protein interactio| STUB1["STUB1"]
MAPT["MAPT"] -->|regulates| HSPA1A_1["HSPA1A"]
Bifunctional_PROTACs["Bifunctional PROTACs"] -->|targets| HSPA1A_2["HSPA1A"]
HSPA1A_3["HSPA1A"] -->|regulates| tau_protein["tau protein"]
HSPA1A_4["HSPA1A"] -->|regulates| proteasomal_degradation_p["proteasomal degradation pathway"]
style HSPA1A fill:#ce93d8,stroke:#333,color:#000
style STUB1 fill:#ce93d8,stroke:#333,color:#000
style MAPT fill:#ce93d8,stroke:#333,color:#000
style HSPA1A_1 fill:#ce93d8,stroke:#333,color:#000
style Bifunctional_PROTACs fill:#4fc3f7,stroke:#333,color:#000
style HSPA1A_2 fill:#4fc3f7,stroke:#333,color:#000
style HSPA1A_3 fill:#4fc3f7,stroke:#333,color:#000
style tau_protein fill:#4fc3f7,stroke:#333,color:#000
style HSPA1A_4 fill:#4fc3f7,stroke:#333,color:#000
style proteasomal_degradation_p fill:#81c784,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix5 supports1 contradicts
Supports
Folding or holding?-Hsp70 and Hsp90 chaperoning of misfolded proteins in neurodegenerative disease.
Supports
The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system.
Supports
Mechanism of Tau protein incorporation into exosomes via cooperative recognition of KFERQ-like motifs by LAMP2A and HSP70.
Contradicts
From sleep to cancer to neurodegenerative disease: the crucial role of Hsp70 in maintaining cellular homeostasis and potential therapeutic implications.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HSPA1A
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HSPA1A.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0511
Events (7d)
0
Price History
▲5.2%💾 Resource Usage
LLM Tokens
18,738
$0.1124
Total Cost
$0.1124
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we orally administer the lead bifunctional PROTAC (≥10 mg/kg, BID) to PS19 mice (expressing P301S human tau) for 8 weeks, THEN hippocampal tau pathology (AT8-positive insoluble aggregates) will be | ≥50% reduction in Sarkozy-insoluble AT8 signal by IHC (stereology, two independent raters); Morris water maze hidden platform latency improved by ≥20% vs. vehic | — no observation — | pending | 0.35 |
| IF we synthesize bifunctional PROTACs that simultaneously engage HSP70's substrate-binding domain (SBD) and recruit CHIP ubiquitin ligase specifically to tau complexes (HSPA1A-CIP4X interface), THEN s | ≥40% reduction in Sarkozy-soluble tau (12-16 kDa fragment) as measured by quantitative immunoblot with HT7/Tau5 antibody pair; tau ubiquitination (K48-linked) w | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF we synthesize bifunctional PROTACs that simultaneously engage HSP70's substrate-binding domain (SBD) and recruit CHIP ubiquitin ligase specifically to tau complexes (HSPA1A-CIP4X interface), THEN soluble tau levels will decrease by ≥40% within 72 hours in iPSC-derived cortical neurons from a tauo
Predicted outcome: ≥40% reduction in Sarkozy-soluble tau (12-16 kDa fragment) as measured by quantitative immunoblot with HT7/Tau5 antibody pair; tau ubiquitination (K48
Falsification: Soluble tau fails to decrease by <30% despite confirmed HSP70-SBD engagement (via SPR, Kd < 200 nM) and CHIP recruitment (co-IP evidence); OR global proteasome activity drops by >25% (chymotrypsin-lik
pendingconf 35%
IF we orally administer the lead bifunctional PROTAC (≥10 mg/kg, BID) to PS19 mice (expressing P301S human tau) for 8 weeks, THEN hippocampal tau pathology (AT8-positive insoluble aggregates) will be reduced by ≥50% without compromising HSP70-dependent protein quality control, as evidenced by unchan
Predicted outcome: ≥50% reduction in Sarkozy-insoluble AT8 signal by IHC (stereology, two independent raters); Morris water maze hidden platform latency improved by ≥20%
Falsification: AT8 pathology fails to reduce by <40% despite confirmed PROTAC brain penetration (AUC > 2 μM·h in cortex); OR HSP70 client proteins (e.g., p53, c-JUN) show ≥40% turnover increase in hippocampus; OR Mo
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.